Spera Pharma, Inc

SPERA PHARMA (SPERA) was spun out from Takeda Pharmaceuticals and became a wholly owned subsidiary of Bushu Pharmaceuticals on July 1, 2017 in Osaka, Japan. On March 2, 2020, Iwaki & Co., Ltd acquired SPERA from Bushu. The IWAKI Group transitioned to a holding company structure under the new name Astena Group on June 1, 2021. SPERA has about 250 employees including researchers and technical specialists in the areas of process chemistry, formulation, and analysis, whose prior work with Takeda gave them broad exposure to all aspects of pharmaceutical R&D, manufacturing, and life cycle management across myriad pharmaceutical products and...

Cdmo,cmc,drug product,api,analytical development,sterile injectables,solid dosage forms,process development,scale-up,gmp manufacturing,oncology,high potency,hapi,peptides,and small molecules

Spera pharma, inc operates in the Pharmaceutical manufacturing industry.

Spera pharma, inc's revenue is 11m - 100m

Spera pharma, inc has 11 - 50 employees.